Prevent small-for-size syndrome using dual grafts in living donor liver transplantation.

Department of Hepato-bilio-pancreatology Surgery and Division of Liver Transplantation, West China Hospital, West China Medical School of Sichuan University, Chengdu, China.
Journal of Surgical Research (Impact Factor: 2.12). 02/2009; 155(2):261-7. DOI: 10.1016/j.jss.2009.01.001
Source: PubMed

ABSTRACT The growing gap between the number of patients waiting for transplantation and available organs is still the main issue facing the transplant community. The major limitation of adult-to-adult living donor liver transplantation (LDLT) is the small-for-size problem because of the concern of donor safety. We report preliminary experiences for preventing small-for-size syndrome using dual grafts from one right lobe without the middle hepatic vein and one left lateral segment in adult-to-adult LDLT.
One hundred ten cases of adult-to-adult LDLT were performed in West China Hospital of Sichuan University from January 2002 to August 2007, and there were 16 small-for-size (SFS) grafts in all grafts. Dual grafts LDLT was performed for six patients with end-stage liver disease, consisting of five cases from one right lobe without the middle hepatic vein and one left lateral segment, and one case from two left lobes.
All living donors underwent a full recovery from the operation without persistent complications. Four recipients died of sepsis, one recipient received re-transplantation, and three recipients received transplenic artery embolization in the recipients with SFS grafts. All recipients with dual grafts displayed good graft function and a majority of grafts showed normal triangular-shape regeneration of their respective liver grafts. Only in one left lateral segment atrophy occurred, graft hepatectomy was not required.
Dual grafts from one right lobe without the middle hepatic vein and one left lateral segment in adult-to-adult LDLT can prevent the small-for-size problem and yet secure the safety of the donors.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The site of Finch Camp in the middle Queen Creek area of Arizona, southeast of Phoenix, has produced some of the earliest evidence of utilitarian pottery use in the US Southwest. Using multiple lines of evidence from vessel morphology, surface alteration, and minute fatty acid residues in vessel walls, I evaluate the nascent function of the earliest vessels (mostly neckless jars, or tecomates) and infer a diachronic process of functional expansion from about 350 B.C.–A.D. 400. This evidence provides robust evidence for evaluating various theoretical models of pottery origins. I argue that utilitarian pottery was initially adopted in connection with the intensification of small particulate plant foods (e.g., seeds, grains) and increasing household-level control over resources. Further, vessel functions may have expanded during the early centuries A.D. in response to women’s task-scheduling conflicts stemming from increasing residential stability and growing reliance on low-level horticulture.Highlights► Pottery adoption at Finch Camp reflected utilitarian, subsistence-related concerns. ► The earliest pots were tecomates, which are versatile utilitarian containers. ► Tecomates were used to intensively process small particulate plant foods. ► Increased pottery use reflected changes in women’s subsistence obligations. ► Processes of pottery adoption were regionally variable and historically contingent.
    Journal of Anthropological Archaeology 06/2011; 30(2):220-234. DOI:10.1016/j.jaa.2011.03.001 · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Small-for-size syndrome remains the greatest limiting factor of expanding segmental liver transplantation from living donors. Portal hyperperfusion is considered to substantially contribute to small-for-size syndrome. We investigated the impact of continuous portal infusion of prostaglandin E1 (PGE1) on small-for-size grafts (SFSGs) in adult-to-adult living-donor liver transplantation (LDLT). METHODS: From July 2003 to December 2009, LDLT was performed in 122 patients. We introduced continuous portal infusion of PGE1 to five SFSG patients (PG group) from November 2007 to December 2009 and retrospectively compared them with a historical control group of eight relevant SFSG patients without PGE1 infusion (non-PG group) from July 2003 to October 2007 to determine the safety and efficacy of continuous PGE1 portal infusion for SFSGs. Splenectomy cases were excluded from analysis. RESULTS: The PG group demonstrated significantly lower postoperative portal pressure than the non-PG group. Moreover, the PG group demonstrated significantly improved liver function in the early posttransplantation period and significantly better recovery from hyperammonemia at 1 week after transplantation and from hyperbilirubinemia in the late posttransplantation period. Overall survival was significantly better in the PG group than in the non-PG group. Three patients in the non-PG group died of rejection-related reasons. Interestingly, immunomonitoring assay revealed that antidonor immune responses were significantly accelerated in the non-PG group compared with the PG group after LDLT. In contrast, the PG group showed well-suppressed antidonor immune responses. CONCLUSION: Continuous portal infusion of PGE1 for SFSG attenuated portal hypertension, improved graft function, and suppressed antidonor immune responses, resulting in better survival.
    Transplantation 04/2013; DOI:10.1097/TP.0b013e31829150a4 · 3.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the outcome of living donor liver transplantation (LDLT) recipients transplanted with small-for-size grafts (SFSGs). Between November 2001 and December 2010, 196 patients underwent LDLT with right lobe liver grafts at our center. Recipients were divided into 2 treatment groups: group A with an actuarial graft-to-recipient weight ratio (aGRWR) < 0.8% (n = 45) and group B with an aGRWR ≥ 0.8% (n = 151). We evaluated serum liver function markers within 4 wk after transplantation. We also retrospectively evaluated the outcomes of these patients for potential effects related to the recipients, the donors and the transplantation procedures based upon a review of their medical records. Small-for-size syndrome (SFSS) developed in 7 of 45 patients (15.56%) in group A and 9 of 151 patients (5.96%) in group B (P = 0.080). The levels of alanine aminotransferase and aspartate aminotransferase in group A were higher than those in group B during early period after transplantation, albeit not significantly. The cumulative 1-, 3- and 5-year liver graft survival rates were 82.22%, 71.11% and 71.11% for group A and 81.46%, 76.82%, and 75.50% for group B patients, respectively (P = 0.623). However, univariate analysis of risk factors associated with graft survival in group A demonstrated that the occurrence of SFSS after LDLT was the only significant risk factor affecting graft survival (P < 0.001). Furthermore, multivariate analysis of our data did not identify any additional significant risk factors accounting for poor graft survival. Our study suggests that LDLT recipients with an aGRWR < 0.8% may have liver graft outcomes comparable to those who received larger size grafts. Further studies are required to ascertain the safety of using SFSGs.
    World Journal of Gastroenterology 01/2014; 20(1):282-9. DOI:10.3748/wjg.v20.i1.282 · 2.43 Impact Factor